NCT03850574 2025-08-26
TUSCANY
Aptose Biosciences Inc.
Phase 1/2 Recruiting
Clinical Trials
4 trialsNCT06232694 2024-01-31
Clinical Study Protocol of IAV-induced Remission Followed by Consolidation Therapy With MDCyta+Ven in ND-AML
The First Affiliated Hospital with Nanjing Medical University
Phase NA Recruiting
NCT05448599 2023-03-15
A Clinical Study of 6MW3211 Monotherapy or Combination Therapy for AML or MDS
Mabwell (Shanghai) Bioscience Co., Ltd.
Phase 1/2 Unknown
NCT05001451 2022-07-20
Study of GDX012 in Patients With MRD Positive AML
GammaDelta Therapeutics Limited
Phase 1 Terminated